维利帕尼或安慰剂联合顺铂与依托泊苷治疗广泛期小细胞肺癌的随机II期试验:ECOG-ACRIN 2511研究
本研究为随机II期试验,纳入128例未经治疗的广泛期小细胞肺癌患者,按性别和血清乳酸脱氢酶水平分层,随机接受顺铂+依托泊苷联合维利帕尼或安慰剂治疗。主要终点无进展生存期在维利帕尼组显示获益信号,研究达到预设终点,但总生存期无显著差异,且男性高乳酸脱氢酶患者亚组获益显著。
要点
- 维利帕尼组中位无进展生存期6.1个月 vs 安慰剂组5.5个月(分层HR 0.63,单侧P=0.01),研究达到预设终点。
- 中位总生存期10.3 vs 8.9个月(分层HR 0.83,单侧P=0.17),无显著差异。
- 男性高乳酸脱氢酶患者亚组无进展生存期HR 0.34(80%CI 0.22-0.51),其他分层无获益证据(HR 0.81,80%CI 0.60-1.09)。
核心结论
- 在未经治疗的广泛期小细胞肺癌患者中,一线化疗联合维利帕尼显示出疗效信号,研究达到预设终点。
研究设计与样本
- 随机II期试验,纳入128例未经治疗的广泛期小细胞肺癌患者,按性别和血清乳酸脱氢酶水平分层。
- 患者随机接受4个3周周期的顺铂(第1天75 mg/m2静脉)和依托泊苷(第1至3天100 mg/m2)联合维利帕尼(第1至7天100 mg口服每日两次)或安慰剂。
- 主要终点为无进展生存期,使用单侧0.10水平log-rank检验,研究有88%把握度证明无进展生存风险降低37.5%。
主要发现
- 维利帕尼组 vs 安慰剂组中位无进展生存期:6.1 vs 5.5个月(未分层HR 0.75,单侧P=0.06;分层HR 0.63,单侧P=0.01), favoring 维利帕尼组。
- 维利帕尼组 vs 安慰剂组中位总生存期:10.3 vs 8.9个月(分层HR 0.83,80%CI 0.64-1.07,单侧P=0.17)。
- 维利帕尼组 vs 安慰剂组总缓解率:71.9% vs 65.6%(双侧P=0.57)。
- 无进展生存期存在显著的治疗与分层交互作用:男性高乳酸脱氢酶患者显著获益(HR 0.34,80%CI 0.22-0.51),其他分层无获益证据(HR 0.81,80%CI 0.60-1.09)。
- ≥3级血液学毒性在维利帕尼组更常见:CD4淋巴细胞减少(8% vs 0%;P=0.06)和中性粒细胞减少(49% vs 32%;P=0.08),但治疗实施相当。
关键数值与推荐
- 研究达到预设主要终点:分层无进展生存期HR 0.63,单侧P=0.01。
- 总生存期分层HR 0.83,80%CI 0.64-1.07,单侧P=0.17,未达统计学显著。
- 总缓解率71.9% vs 65.6%,双侧P=0.57,无显著差异。
临床怎么用
- 作者认为,在广泛期小细胞肺癌一线化疗中加入维利帕尼显示出疗效信号,研究达到预设终点。
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy against small-cell lung cancer (SCLC) in preclinical studies. We evaluated the combination of veliparib with cisplatin and etoposide (CE; CE+V) doublet in untreated, extensive-stage SCLC (ES-SCLC). MATERIALS AND METHODS: Patients with ES-SCLC, stratified by sex and serum lactate dehydrogenase levels, were randomly assigned to receive four 3-week cycles of CE (75 mg/m2 intravenously on day 1 and 100 mg/m2 on days 1 through 3) along with veliparib (100 mg orally twice per day on days 1 through 7) or placebo (CE+P). The primary end point was progression-free survival (PFS). Using an overall one-sided 0.10-level log-rank test, the study had 88% power to demonstrate a 37.5% reduction in the PFS hazard rate. RESULTS: A total of 128 eligible patients received treatment on protocol. The median age was 66 years, 52% of patients were men, and Eastern Cooperative Oncology Group performance status was 0 for 29% of patients and 1 for 71%. The respective median PFS for the CE+V arm versus the CE+P arm was 6.1 versus 5.5 months (unstratified hazard ratio [HR], 0.75 [one-sided P = .06]; stratified HR, 0.63 [one-sided P = .01]), favoring CE+V. The median overall survival was 10.3 versus 8.9 months (stratified HR, 0.83; 80% CI, 0.64 to 1.07; one-sided P = .17) for the CE+V and CE+P arms, respectively. The overall response rate was 71.9% versus 65.6% (two-sided P = .57) for CE+V and CE+P, respectively. There was a significant treatment-by-strata interaction in PFS: Male patients with high lactate dehydrogenase levels derived significant benefit (PFS HR, 0.34; 80% CI, 0.22 to 0.51) but there was no evidence of benefit among patients in other strata (PFS HR, 0.81; 80% CI, 0.60 to 1.09). The following grade ≥ 3 hematology toxicities were more frequent in the CE+V arm than the CE+P arm: CD4 lymphopenia (8% v 0%; P = .06) and neutropenia (49% v 32%; P = .08), but treatment delivery was comparable. CONCLUSION: The addition of veliparib to frontline chemotherapy showed signal of efficacy in patients with ES-SCLC and the study met its prespecified end point.
引用
- Owonikoko TK, Dahlberg SE, Sica GL, et al. Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. J Clin Oncol. 2018. PMID: 30523756. doi:10.1200/JCO.18.00264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。